We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+28.11%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$1.82B
AUM Growth
+$1.6B
Cap. Flow
+$16.1M
Cap. Flow %
0.88%
Top 10 Hldgs %
91.96%
Holding
76
New
25
Increased
14
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$8.59M
2
ESPR
Esperion Therapeutics
ESPR
+$7.67M
3
MDT icon
Medtronic
MDT
+$7.27M
4
ICUI icon
ICU Medical
ICUI
+$7.06M
5
EHC icon
Encompass Health
EHC
+$5.8M

Top Sells

Rank Stock Value
1
HOLX
Hologic
HOLX
+$19.2M
2
PFE icon
Pfizer
PFE
+$16.7M
3
SNY icon
Sanofi
SNY
+$15.1M
4
SIBN icon
SI-BONE Inc
SIBN
+$9.12M
5
CI icon
Cigna
CI
+$6.7M

Sector Composition

Rank Sector Weight
1 Healthcare 11.6%
2 Industrials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
51
DELISTED
Alexion Pharmaceuticals
ALXN
$466K 0.03%
+4,148
New +$440K
GNCA
52
DELISTED
Genocea Biosciences, Inc.
GNCA
$276K 0.02%
119,979
-144,328
-55% -$332K
PCVX icon
53
Vaxcyte
PCVX
$8.4B
$216K 0.01%
+6,827
New +$220K
ADCT icon
54
ADC Therapeutics
ADCT
$142M
$206K 0.01%
+4,410
New +$167K
AMGN icon
55
Amgen
AMGN
$219B
– –
-13,193
Closed -$2.67M
ATRC icon
56
AtriCure
ATRC
$2.02B
– –
-33,453
Closed -$1.12M
AVDL
57
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-87,676
Closed -$696K
AVTR icon
58
Avantor
AVTR
$8.91B
– –
-249,382
Closed -$3.12M
AXSM icon
59
Axsome Therapeutics
AXSM
$10.9B
– –
-12,367
Closed -$728K
BMRN icon
60
BioMarin Pharmaceuticals
BMRN
$11.8B
– –
-28,599
Closed -$2.42M
CRL icon
61
Charles River Laboratories
CRL
$12.5B
– –
-13,147
Closed -$1.66M
DVA icon
62
DaVita
DVA
$11.5B
– –
-27,164
Closed -$2.07M
HCA icon
63
HCA Healthcare
HCA
$88B
– –
-5,666
Closed -$509K
IOVA icon
64
Iovance Biotherapeutics
IOVA
$2.75B
– –
-20,207
Closed -$605K
LAB icon
65
Standard BioTools
LAB
$305M
– –
-232,291
Closed -$590K
MGNX icon
66
MacroGenics
MGNX
$253M
– –
-87,703
Closed -$510K
OVID icon
67
Ovid Therapeutics
OVID
$489M
– –
-116,297
Closed -$347K
PETS icon
68
PetMed Express
PETS
$42.1M
– –
-9,964
Closed -$287K
PFE icon
69
Pfizer
PFE
$148B
– –
-537,698
Closed -$16.7M
TAK icon
70
Takeda Pharmaceutical
TAK
$54.4B
– –
-156,120
Closed -$2.37M
RCM
71
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-484,801
Closed -$4.41M
KDMN
72
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-61,188
Closed -$256K
PRAH
73
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-38,817
Closed -$3.22M
GWPH
74
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-16,890
Closed -$1.48M
1 2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Endurant Capital Management held 76 positions worth $1.82B, up 727% from $221M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Endurant Capital Management's Q2 2020 filing shows 25 new, 14 increased, 16 reduced and 20 closed positions. Its largest new stake was Esperion Therapeutics: 183,249 shares worth $9.4M. The largest sale was Hologic, an estimated $19.2M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 90% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q2 2020 buy was Esperion Therapeutics: 183,249 shares worth $9.4M.
  • Endurant Capital Management added most to Centene in Q2 2020, an estimated $8.59M increase.
  • Endurant Capital Management's biggest Q2 2020 reduction was Hologic, cutting an estimated $19.2M.
  • Endurant Capital Management fully exited Pfizer in Q2 2020, selling an estimated $16.7M.
  • Endurant Capital Management's ten largest holdings make up 92% of its $1.82B portfolio in Q2 2020.
  • Endurant Capital Management opened 25 new positions and closed 20 in Q2 2020.
  • Endurant Capital Management's portfolio value rose 727% quarter-over-quarter to $1.82B.

Based on Endurant Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.